A STUDY OF CUTANEOUS ADVERSE REACTIONS TO DRUGS
DOI:
https://doi.org/10.66344/jpad.32.1.2022.1796Abstract
ABSTRACT Background: Due to the casual and wide use of the drugs, the incidence of harmful effects have increased dramatically. These effects may present as toxic effect, side effect or adverse effects. The study is conducted to assess the frequency, pattern of CADRs and culprit drugs. Method: This study was carried out for one year in Rohilkhand Medical College and Hospital, Bareilly, U.P. It included 114 patients showing clinical manifestations of CADR. Result: FDE was the most common CADR, in 46 (40.35%) patients followed by 22 (19.30%) patients with maculopapular rash. Out of114 patients enrolled, 19 (16.67%) were found to have SCADR. Most common severe cutaneous adverse reactions was erythroderma (31.58%), followed by SJS (26.32%). Most common culprit class of drugs were antibiotic (30.70%) followed by nonsteroidal anti‑inflammatory drugs (22.81%), antifungal (12.28%). As per WHO-UMC causality assessment, in the study, certain, probable and possible categories were 7.89%, 38.60% and 31.58% respectively. Conclusion: It was found that fixed drug eruption was the most common type of morphological pattern of CADRs and antibiotics was the most common culprit class of drugs. Keywords: Cutaneous adverse drug reactions, SJS, TEN, FDE, Antibiotics.Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.